As interest rates and economic indicators change in global markets, Hong Kong’s tech sector remains a hot topic for investors seeking growth opportunities amid broader market volatility. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation potential, market demand, and resilience to economic fluctuations.
name
increase in revenue
revenue growth
growth assessment
Washion Holdings
22.37%
25.47%
★★★★★☆
MedCai Healthcare Holdings
48.74%
48.78%
★★★★★☆
Inspur Digital Enterprise Technology
23.28%
38.76%
★★★★★☆
remegen
26.23%
52.03%
★★★★★☆
Cowell E Holdings
31.68%
35.44%
★★★★★
Innovent Biologics
22.00%
59.21%
★★★★★☆
Akiso
33.50%
53.28%
★★★★★
Biocytogen Pharmaceuticals (Beijing)
21.53%
109.17%
★★★★★☆
beijing air dock technology
37.47%
93.35%
★★★★★☆
Sichuan Cologne-Biotech Biopharmaceutical
24.61%
7.62%
★★★★★☆
Click here to see the complete list of 43 stocks in the SEHK High Growth Technology Stock and AI Stock Screener.
Below, we spotlight some of our favorites from our exclusive screener.
Simply Wall Street Growth Rating: ★★★★☆
Overview: BYD Electronic (International) Company Limited is an investment holding company focused on designing, manufacturing, assembling and selling mobile phone components and modules in China and around the world, with a market capitalization of HK$74.24 billion.
What it does: BYD Electronic (International) Company Limited derives its revenue primarily through the manufacture, assembly and sale of mobile phone components and modules, with reported sales of C$152.36 billion. The company operates both in China and overseas, leveraging its expertise in electronics manufacturing services to serve customers around the world.
BYD Electronic (International) showed strong performance, with sales in the first half of 2024 significantly increasing by 39.9% to RMB 78.58 billion, reflecting strong market demand. The company’s profit growth rate is particularly strong, with a forecast of 24.9% per year, higher than the overall Hong Kong market average of 12.2%. This growth trajectory is sustained by the strategic initiatives highlighted at the Macquarie Asia TMT Conference, and is underlined by the recent earnings report, which showed stable net profit and EPS. Despite the challenge of consistently outperforming industry averages in revenue growth, with a steady but expected 12% annual slowdown, BYD Electronics is poised to continue to innovate, gain market share, and maintain its position in high-growth markets. We are committed to greater relevance and competitiveness.
story continues
SEHK:285 Breakdown of revenue and expenses as of October 2024
Simply Wall Street Growth Rating: ★★★★☆
Overview: Tencent Holdings Limited is an investment holding company that provides value-added services, online advertising, fintech and business services in China and abroad, with a market capitalization of approximately HK$3.88 trillion.
Business: Tencent mainly generates revenue from value-added services (RMB 302.28 billion), online advertising (RMB 111.89 billion), and fintech and business services (RMB 209.17 billion). The company’s diverse businesses span digital content, social networks, payment systems, and cloud solutions across a variety of markets.
Tencent Holdings has demonstrated a solid financial trajectory with a significant expected annual profit growth rate of 12.9%, higher than the Hong Kong market average of 12.2%, as it weathers market fluctuations and strategic acquisitions such as the potential acquisition of Ubisoft. are. This growth was supported by an 8.2% increase in annual revenue, demonstrating Tencent’s ability to effectively scale its core business. Furthermore, R&D investment remains the cornerstone of Tencent’s strategy to maintain technological leadership and drive future innovation. These expenses are consistently aligned with the company’s broader growth objectives and ensure continued advancement of its product offerings and market position.
SEHK:700 profit and revenue growth as of October 2024
Simply Wall Street Growth Rating: ★★★★★★
Overview: Akeso, Inc. is a biopharmaceutical company engaged in the research, development, manufacturing and commercialization of antibody therapeutics with a market capitalization of approximately HK$60.76 billion.
What it does: The Company is focused on the research, development, production and marketing of biopharmaceuticals and generates revenues of C$1.87 billion from these activities.
Akeso, a frontrunner in the biotechnology sector, recently completed a share issue raising HK$1.94 billion, confirming the company’s strong financial position and investor confidence. This infusion is critical as Akeso’s R&D spending remains aggressive and is consistent with its strategic focus on breakthrough cancer treatments such as cadnilimab. Impressively, Akeso is forecasting revenue growth of 33.5% per year, with expected revenue growth soaring at 53.3% per year and expecting it to be profitable within three years. These numbers highlight the company’s potential to transform patient outcomes in oncology through innovative treatments.
SEHK:9926 Breakdown of revenue and expenses as of October 2024
See SEHK’s full lineup of 43 high-growth technology and AI stocks here.
Do you own stocks in these companies? Set up your portfolio with Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio’s performance.
Simply Wall St is your key to unlocking global market trends and is a free, user-friendly app for forward-thinking investors.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
Companies covered in this article include SEHK:285 SEHK:700 and SEHK:9926.
Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.
